Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1
Publication information:
Hemming M, Nathenson M, Lin J-R, Mei S, Du Z, Malik K, Marino-Enriquez A, Jagannathan J, Sorger P, Bertagnolli M, et al. Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1. JCO precision oncology. 2020;4:79–90.